Global Apixaban {Eliquis} Market, By Dosage form (Tablets and Capsule), By Distribution channel (Hospital, Online pharmacies, Retail pharmacies and Clinics), By Route of administration (Oral and Injectable), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Apixaban is an anticoagulant licenced by the Food and Drug Administration (FDA) for the treatment of venous thromboembolic events (blood clots) that occur within a vein. It is used as a replacement for warfarin, and it does not require blood testing or dietary restrictions. Venous thromboembolic events (VTE) can happen without any warning signs or symptoms, and they can go untreated and unnoticed by a healthcare provider. Pain in the leg, swelling in the ankle or foot, redness or obvious discolouration areas, rapid breathing, chest pain, and other symptoms may be associated with pulmonary embolism (PE) or Bleeding and nausea are both common side effects. Bleeding around the spine and allergy reactions are also possible adverse effects. The National Institute for Health and Clinical Excellence recommends apixaban for the prevention of stroke and systemic embolism in patients who have non-valvular atrial fibrillation and at least one of the risk factors listed below: past stroke or transient ischemic attack, age 75 or older, diabetes mellitus, or symptomatic heart failure are also factors to consider. Eliquis is the brand name for the drug apixaban. Factor Xa is a trypsin-like serine protease involved in the coagulation of blood.

Investment through government and private bodies

The market for apixaban is predicted to develop as the prevalence of venous thromboembolism-related disorders rises. Furthermore, the apixaban market is predicted to rise as the number of therapeutic indications for the drug grows. For example, the US Food and Drug Administration authorized Eliquis in 2014 for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the reduction of the risk of recurring PE and DVT after initial therapy. Furthermore, both the government and private organizations are investing heavily in healthcare research and development, which is expected to boost the Apixaban market. Adoption of apixaban is predicted to be hampered by side effects such as an increased risk of thrombotic events following premature withdrawal and bleeding. As a result, the market's growth is projected to be negatively affected.

The global Apixaban {Eliquis} market is segmented based on dosage form, distribution channel, route of administration and region.

On the basis of dosage form, the global Apixaban {Eliquis} market is segmented into Tablets and Capsules. Based on distribution channel, the target market is segmented into Hospital, Retail pharmacies, Online pharmacies and Clinics. On the basis of route of administration, the target market is segmented into Oral and Injectable.

Regional Insights:

On region the global Apixaban {Eliquis} market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global Apixaban {Eliquis} market. The high prevalence of cardiovascular disorders that require anticoagulant treatment, as well as new product launches around the globe, are driving market expansion in this region. Furthermore, the rising prevalence of venous thromboembolic events has boosted apixaban's popularity in the North American market. According to a 2010 study published in the American Journal of Preventive Medicine, venous thromboembolism (VTE) affects roughly 300,000-600,000 persons in the United States each year, resulting in significant mortality. Furthermore, venous thromboembolism (VTE) problem can affect people of various races, ages, and genders. Due to increased healthcare initiatives by various governments, the Asia Pacific market is predicted to grow significantly over the forecast period, followed by the Europe market.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global Apixaban {Eliquis} market report based on dosage form, distribution channel, route of administration and region.

Global Apixaban {Eliquis} Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global Apixaban {Eliquis} market includes Abbott, Roche, Bristol-Myers Squibb, Siemens, Portola Pharmaceuticals, C. H. Boehringer Sohn, Pfizer, CoaguSense and Alere. To establish a dominant position in the market, industry players are concentrating on the development of new technologies, mergers, and collaborations. For example, in 2016, Pfizer and Bristol-Myers Squibb partnered with Portola Pharmaceuticals to commercialize and develop investigational Andexanet Alfa, a clinical phase 3 drug that is being developed to reverse the anticoagulant effect of Factor Xa inhibitors and will be beneficial to patients taking Eliquis who are experiencing major bleeding problems.

• Abbott.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Roche
• Bristol-Myers Squibb
• Siemens
• Portola Pharmaceuticals
• C. H. Boehringer Sohn
• Pfizer
• CoaguSense
• Alere

 “*” marked represents similar segmentation in other categories in the respective section